Ambee Pharmaceuticals（AMBEEPHA）株式概要アンビー・ファーマシューティカルズPLCは、バングラデシュで医薬品、化学薬品、医療用医薬品、その他製剤の製造・販売を行っている。 詳細AMBEEPHA ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績2/6財務の健全性2/6配当金0/6リスク分析負債は営業キャッシュフローで十分にカバーされていない 意味のある時価総額がありません ( BDT2B )意味のある収益がありません ( BDT158M )すべてのリスクチェックを見るAMBEEPHA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value৳Current Price৳780.3017.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-13m352m2016201920222025202620282031Revenue ৳249.1mEarnings ৳8.7mAdvancedSet Fair ValueView all narrativesAmbee Pharmaceuticals PLC 競合他社Silco PharmaceuticalsSymbol: DSE:SILCOPHLMarket cap: ৳2.3bAdvent PharmaSymbol: DSE:ADVENTMarket cap: ৳1.4bCentral PharmaceuticalsSymbol: DSE:CENTRALPHLMarket cap: ৳1.1bSilva PharmaceuticalsSymbol: DSE:SILVAPHLMarket cap: ৳1.8b価格と性能株価の高値、安値、推移の概要Ambee Pharmaceuticals過去の株価現在の株価৳780.3052週高値৳929.0052週安値৳681.00ベータ-0.241ヶ月の変化2.23%3ヶ月変化0.74%1年変化1.31%3年間の変化48.54%5年間の変化90.74%IPOからの変化4,828.21%最新ニュースNew Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Revenue is less than US$5m (৳158m revenue, or US$1.3m). Market cap is less than US$100m (৳1.87b market cap, or US$15.2m).Reported Earnings • Jun 02Third quarter 2026 earnings released: EPS: ৳0.40 (vs ৳0.85 in 3Q 2025)Third quarter 2026 results: EPS: ৳0.40 (down from ৳0.85 in 3Q 2025). Revenue: ৳28.3m (down 48% from 3Q 2025). Net income: ৳964.0k (down 53% from 3Q 2025). Profit margin: 3.4% (down from 3.8% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 27Ambee Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 29, 2026Ambee Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 25Ambee Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026Ambee Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026お知らせ • Nov 10Ambee Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 12, 2025Ambee Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 12, 2025最新情報をもっと見るRecent updatesNew Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Revenue is less than US$5m (৳158m revenue, or US$1.3m). Market cap is less than US$100m (৳1.87b market cap, or US$15.2m).Reported Earnings • Jun 02Third quarter 2026 earnings released: EPS: ৳0.40 (vs ৳0.85 in 3Q 2025)Third quarter 2026 results: EPS: ৳0.40 (down from ৳0.85 in 3Q 2025). Revenue: ৳28.3m (down 48% from 3Q 2025). Net income: ৳964.0k (down 53% from 3Q 2025). Profit margin: 3.4% (down from 3.8% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 27Ambee Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 29, 2026Ambee Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 25Ambee Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026Ambee Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026お知らせ • Nov 10Ambee Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 12, 2025Ambee Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 12, 2025お知らせ • Nov 04Ambee Pharmaceuticals PLC announces Annual dividend, payable on January 18, 2026Ambee Pharmaceuticals PLC announced Annual dividend of BDT 1.0000 per share payable on January 18, 2026, ex-date on November 23, 2025 and record date on November 20, 2025.お知らせ • Nov 03Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 18, 2025Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 18, 2025, at 11:00 Central Asia Standard Time. Location: 184/1, tejgaon industrial area, dhaka-1208, Bangladeshお知らせ • Oct 27Ambee Pharmaceuticals PLC to Report Fiscal Year 2025 Results on Oct 30, 2025Ambee Pharmaceuticals PLC announced that they will report fiscal year 2025 results on Oct 30, 2025お知らせ • Apr 24Ambee Pharmaceuticals PLC to Report Q3, 2025 Results on Apr 27, 2025Ambee Pharmaceuticals PLC announced that they will report Q3, 2025 results on Apr 27, 2025お知らせ • Jan 16Ambee Pharmaceuticals PLC to Report Q2, 2025 Results on Jan 22, 2025Ambee Pharmaceuticals PLC announced that they will report Q2, 2025 results on Jan 22, 2025Declared Dividend • Nov 13Dividend of ৳1.00 announcedShareholders will receive a dividend of ৳1.00. Ex-date: 3rd December 2024 Payment date: 23rd January 2025 Dividend yield will be 0.1%, which is lower than the industry average of 2.5%.お知らせ • Nov 12Ambee Pharmaceuticals PLC to Report Q1, 2025 Results on Nov 14, 2024Ambee Pharmaceuticals PLC announced that they will report Q1, 2025 results on Nov 14, 2024お知らせ • Nov 11Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2024Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2024, at 11:00 Central Asia Standard Time. Location: industrial area, dhaka-1208, Bangladeshお知らせ • Nov 06Ambee Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Nov 10, 2024Ambee Pharmaceuticals PLC announced that they will report fiscal year 2024 results on Nov 10, 2024New Risk • Jun 30New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Revenue is less than US$5m (৳205m revenue, or US$1.7m). Market cap is less than US$100m (৳1.80b market cap, or US$15.3m).Reported Earnings • Jun 27Third quarter 2024 earnings released: EPS: ৳0.80 (vs ৳0.69 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.80 (up from ৳0.69 in 3Q 2023). Revenue: ৳45.3m (down 8.2% from 3Q 2023). Net income: ৳1.91m (up 15% from 3Q 2023). Profit margin: 4.2% (up from 3.4% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 23Ambee Pharmaceuticals PLC to Report Q3, 2024 Results on Apr 28, 2024Ambee Pharmaceuticals PLC announced that they will report Q3, 2024 results on Apr 28, 2024New Risk • Feb 11New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (20% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Revenue is less than US$5m (৳209m revenue, or US$1.9m). Market cap is less than US$100m (৳1.93b market cap, or US$17.6m).Reported Earnings • Feb 07Second quarter 2024 earnings released: EPS: ৳0.60 (vs ৳0.35 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.60 (up from ৳0.35 in 2Q 2023). Revenue: ৳58.5m (up 2.7% from 2Q 2023). Net income: ৳1.45m (up 72% from 2Q 2023). Profit margin: 2.5% (up from 1.5% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 22Ambee Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024Ambee Pharmaceuticals PLC announced that they will report Q2, 2024 results on Jan 28, 2024Upcoming Dividend • Nov 19Upcoming dividend of ৳1.50 per share at 0.2% yieldEligible shareholders must have bought the stock before 26 November 2023. Payment date: 14 January 2024. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).お知らせ • Nov 07Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 14, 2023Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 14, 2023, at 11:00 Bangladesh Standard Time.お知らせ • Oct 28Ambee Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Nov 02, 2023Ambee Pharmaceuticals PLC announced that they will report fiscal year 2023 results on Nov 02, 2023New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 23% per year over the past 5 years. High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Revenue is less than US$5m (৳191m revenue, or US$1.7m). Market cap is less than US$100m (৳1.99b market cap, or US$18.0m).New Risk • Jul 13New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 23% per year over the past 5 years. High level of non-cash earnings (26% accrual ratio). Minor Risks Revenue is less than US$5m (৳191m revenue, or US$1.8m). Market cap is less than US$100m (৳1.29b market cap, or US$11.9m).Reported Earnings • Jul 11Third quarter 2023 earnings released: EPS: ৳0.69 (vs ৳0.40 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.69 (up from ৳0.40 in 3Q 2022). Revenue: ৳49.4m (up 30% from 3Q 2022). Net income: ৳1.67m (up 74% from 3Q 2022). Profit margin: 3.4% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 17Second quarter 2023 earnings released: EPS: ৳0.35 (vs ৳0.24 in 2Q 2022)Second quarter 2023 results: EPS: ৳0.35 (up from ৳0.24 in 2Q 2022). Revenue: ৳56.9m (down 10.0% from 2Q 2022). Net income: ৳841.0k (up 49% from 2Q 2022). Profit margin: 1.5% (up from 0.9% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Dec 11Full year 2022 earnings released: EPS: ৳3.36 (vs ৳5.42 loss in FY 2021)Full year 2022 results: EPS: ৳3.36 (up from ৳5.42 loss in FY 2021). Revenue: ৳181.0m (up 83% from FY 2021). Net income: ৳8.06m (up ৳21.1m from FY 2021). Profit margin: 4.5% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.お知らせ • Nov 23Ambee Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022Ambee Pharmaceuticals Limited announced the board of directors has recommended 10% cash dividend for the year ended June 30, 2022. Date of AGM is December 31, 2022.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jul 13Ambee Pharmaceuticals Limited Appoints Ms. Kazi Tanzzina Ferdous as Managing DirectorAmbee Pharmaceuticals Limited announced the appointment of Ms. Kazi Tanzzina Ferdous as the Managing Director of the Company.Reported Earnings • May 29Third quarter 2022 earnings released: EPS: ৳0.40 (vs ৳0.30 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.40 (up from ৳0.30 in 3Q 2021). Revenue: ৳38.0m (down 3.6% from 3Q 2021). Net income: ৳961.0k (up 34% from 3Q 2021). Profit margin: 2.5% (up from 1.8% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Dec 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ৳5.42 loss per share (down from ৳1.52 profit in FY 2020). Revenue: ৳99.0m (down 65% from FY 2020). Net loss: ৳13.0m (down 458% from profit in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.Reported Earnings • Jun 27Full year 2020 earnings released: EPS ৳1.52 (vs ৳1.40 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ৳285.3m (down 11% from FY 2019). Net income: ৳3.64m (up 8.0% from FY 2019). Profit margin: 1.3% (up from 1.0% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Jun 23Upcoming dividend of ৳1.50 per shareEligible shareholders must have bought the stock before 29 June 2021. Payment date: 12 August 2021. Trailing yield: 0.4%. Lower than top quartile of Bangladeshi dividend payers (2.8%). Lower than average of industry peers (1.5%).Is New 90 Day High Low • Feb 04New 90-day low: ৳417The company is down 9.0% from its price of ৳459 on 05 November 2020. The Bangladeshi market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.Is New 90 Day High Low • Jan 20New 90-day low: ৳430The company is down 9.0% from its price of ৳474 on 22 October 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: ৳441The company is down 1.0% from its price of ৳446 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.株主還元AMBEEPHABD PharmaceuticalsBD 市場7D0.8%1.3%1.9%1Y1.3%11.4%11.4%株主還元を見る業界別リターン: AMBEEPHA過去 1 年間で11.4 % の収益を上げたBD Pharmaceuticals業界を下回りました。リターン対市場: AMBEEPHAは、過去 1 年間で11.4 % のリターンを上げたBD市場を下回りました。価格変動Is AMBEEPHA's price volatile compared to industry and market?AMBEEPHA volatilityAMBEEPHA Average Weekly Movement2.6%Pharmaceuticals Industry Average Movement4.1%Market Average Movement4.9%10% most volatile stocks in BD Market7.4%10% least volatile stocks in BD Market2.9%安定した株価: AMBEEPHA 、 BD市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: AMBEEPHAの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1976474Kazi Ferdouswww.ambeepharma.comアンビー・ファーマシューティカルズPLCは、バングラデシュで医薬品、化学薬品、医療用医薬品、その他製剤の製造・販売を行っている。同社は、鎮痛解熱剤、駆虫剤、制酸剤、抗ヒスタミン剤、抗寄生虫剤、抗真菌剤、喘息・鎮咳剤、抗菌剤、抗潰瘍剤、制吐剤、降圧剤など、様々な治療分野の製品を提供している、抗脂血症剤、抗骨関節炎剤、鎮痙剤、抗結核剤、抗潰瘍剤、抗不安・催眠剤、脳血管拡張剤、副腎皮質ステロイド剤、利尿剤、非ステロイド性抗炎症剤、ステロイド性抗炎症剤、血液安定剤、ビタミン・ミネラル。また、錠剤、カプセル剤、液剤、チューブ剤、注射剤などの形態で製品を提供している。同社は製品を輸出している。同社は1976年に設立され、バングラデシュのダッカに本社を置いている。もっと見るAmbee Pharmaceuticals PLC 基礎のまとめAmbee Pharmaceuticals の収益と売上を時価総額と比較するとどうか。AMBEEPHA 基礎統計学時価総額৳1.87b収益（TTM）৳5.53m売上高(TTM)৳157.61m338.8xPER（株価収益率11.9xP/SレシオAMBEEPHA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計AMBEEPHA 損益計算書（TTM）収益৳157.61m売上原価৳84.67m売上総利益৳72.95mその他の費用৳67.42m収益৳5.53m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）2.30グロス・マージン46.28%純利益率3.51%有利子負債／自己資本比率1,867.0%AMBEEPHA の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.1%現在の配当利回り43%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 02:07終値2026/06/10 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ambee Pharmaceuticals PLC 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Revenue is less than US$5m (৳158m revenue, or US$1.3m). Market cap is less than US$100m (৳1.87b market cap, or US$15.2m).
Reported Earnings • Jun 02Third quarter 2026 earnings released: EPS: ৳0.40 (vs ৳0.85 in 3Q 2025)Third quarter 2026 results: EPS: ৳0.40 (down from ৳0.85 in 3Q 2025). Revenue: ৳28.3m (down 48% from 3Q 2025). Net income: ৳964.0k (down 53% from 3Q 2025). Profit margin: 3.4% (down from 3.8% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 27Ambee Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 29, 2026Ambee Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 25Ambee Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026Ambee Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026
お知らせ • Nov 10Ambee Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 12, 2025Ambee Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 12, 2025
New Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Revenue is less than US$5m (৳158m revenue, or US$1.3m). Market cap is less than US$100m (৳1.87b market cap, or US$15.2m).
Reported Earnings • Jun 02Third quarter 2026 earnings released: EPS: ৳0.40 (vs ৳0.85 in 3Q 2025)Third quarter 2026 results: EPS: ৳0.40 (down from ৳0.85 in 3Q 2025). Revenue: ৳28.3m (down 48% from 3Q 2025). Net income: ৳964.0k (down 53% from 3Q 2025). Profit margin: 3.4% (down from 3.8% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 27Ambee Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 29, 2026Ambee Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 25Ambee Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026Ambee Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026
お知らせ • Nov 10Ambee Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 12, 2025Ambee Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 12, 2025
お知らせ • Nov 04Ambee Pharmaceuticals PLC announces Annual dividend, payable on January 18, 2026Ambee Pharmaceuticals PLC announced Annual dividend of BDT 1.0000 per share payable on January 18, 2026, ex-date on November 23, 2025 and record date on November 20, 2025.
お知らせ • Nov 03Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 18, 2025Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 18, 2025, at 11:00 Central Asia Standard Time. Location: 184/1, tejgaon industrial area, dhaka-1208, Bangladesh
お知らせ • Oct 27Ambee Pharmaceuticals PLC to Report Fiscal Year 2025 Results on Oct 30, 2025Ambee Pharmaceuticals PLC announced that they will report fiscal year 2025 results on Oct 30, 2025
お知らせ • Apr 24Ambee Pharmaceuticals PLC to Report Q3, 2025 Results on Apr 27, 2025Ambee Pharmaceuticals PLC announced that they will report Q3, 2025 results on Apr 27, 2025
お知らせ • Jan 16Ambee Pharmaceuticals PLC to Report Q2, 2025 Results on Jan 22, 2025Ambee Pharmaceuticals PLC announced that they will report Q2, 2025 results on Jan 22, 2025
Declared Dividend • Nov 13Dividend of ৳1.00 announcedShareholders will receive a dividend of ৳1.00. Ex-date: 3rd December 2024 Payment date: 23rd January 2025 Dividend yield will be 0.1%, which is lower than the industry average of 2.5%.
お知らせ • Nov 12Ambee Pharmaceuticals PLC to Report Q1, 2025 Results on Nov 14, 2024Ambee Pharmaceuticals PLC announced that they will report Q1, 2025 results on Nov 14, 2024
お知らせ • Nov 11Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2024Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2024, at 11:00 Central Asia Standard Time. Location: industrial area, dhaka-1208, Bangladesh
お知らせ • Nov 06Ambee Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Nov 10, 2024Ambee Pharmaceuticals PLC announced that they will report fiscal year 2024 results on Nov 10, 2024
New Risk • Jun 30New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Revenue is less than US$5m (৳205m revenue, or US$1.7m). Market cap is less than US$100m (৳1.80b market cap, or US$15.3m).
Reported Earnings • Jun 27Third quarter 2024 earnings released: EPS: ৳0.80 (vs ৳0.69 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.80 (up from ৳0.69 in 3Q 2023). Revenue: ৳45.3m (down 8.2% from 3Q 2023). Net income: ৳1.91m (up 15% from 3Q 2023). Profit margin: 4.2% (up from 3.4% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 23Ambee Pharmaceuticals PLC to Report Q3, 2024 Results on Apr 28, 2024Ambee Pharmaceuticals PLC announced that they will report Q3, 2024 results on Apr 28, 2024
New Risk • Feb 11New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (20% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Revenue is less than US$5m (৳209m revenue, or US$1.9m). Market cap is less than US$100m (৳1.93b market cap, or US$17.6m).
Reported Earnings • Feb 07Second quarter 2024 earnings released: EPS: ৳0.60 (vs ৳0.35 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.60 (up from ৳0.35 in 2Q 2023). Revenue: ৳58.5m (up 2.7% from 2Q 2023). Net income: ৳1.45m (up 72% from 2Q 2023). Profit margin: 2.5% (up from 1.5% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 22Ambee Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024Ambee Pharmaceuticals PLC announced that they will report Q2, 2024 results on Jan 28, 2024
Upcoming Dividend • Nov 19Upcoming dividend of ৳1.50 per share at 0.2% yieldEligible shareholders must have bought the stock before 26 November 2023. Payment date: 14 January 2024. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).
お知らせ • Nov 07Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 14, 2023Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 14, 2023, at 11:00 Bangladesh Standard Time.
お知らせ • Oct 28Ambee Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Nov 02, 2023Ambee Pharmaceuticals PLC announced that they will report fiscal year 2023 results on Nov 02, 2023
New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 23% per year over the past 5 years. High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Revenue is less than US$5m (৳191m revenue, or US$1.7m). Market cap is less than US$100m (৳1.99b market cap, or US$18.0m).
New Risk • Jul 13New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 23% per year over the past 5 years. High level of non-cash earnings (26% accrual ratio). Minor Risks Revenue is less than US$5m (৳191m revenue, or US$1.8m). Market cap is less than US$100m (৳1.29b market cap, or US$11.9m).
Reported Earnings • Jul 11Third quarter 2023 earnings released: EPS: ৳0.69 (vs ৳0.40 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.69 (up from ৳0.40 in 3Q 2022). Revenue: ৳49.4m (up 30% from 3Q 2022). Net income: ৳1.67m (up 74% from 3Q 2022). Profit margin: 3.4% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 17Second quarter 2023 earnings released: EPS: ৳0.35 (vs ৳0.24 in 2Q 2022)Second quarter 2023 results: EPS: ৳0.35 (up from ৳0.24 in 2Q 2022). Revenue: ৳56.9m (down 10.0% from 2Q 2022). Net income: ৳841.0k (up 49% from 2Q 2022). Profit margin: 1.5% (up from 0.9% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Dec 11Full year 2022 earnings released: EPS: ৳3.36 (vs ৳5.42 loss in FY 2021)Full year 2022 results: EPS: ৳3.36 (up from ৳5.42 loss in FY 2021). Revenue: ৳181.0m (up 83% from FY 2021). Net income: ৳8.06m (up ৳21.1m from FY 2021). Profit margin: 4.5% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 23Ambee Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022Ambee Pharmaceuticals Limited announced the board of directors has recommended 10% cash dividend for the year ended June 30, 2022. Date of AGM is December 31, 2022.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jul 13Ambee Pharmaceuticals Limited Appoints Ms. Kazi Tanzzina Ferdous as Managing DirectorAmbee Pharmaceuticals Limited announced the appointment of Ms. Kazi Tanzzina Ferdous as the Managing Director of the Company.
Reported Earnings • May 29Third quarter 2022 earnings released: EPS: ৳0.40 (vs ৳0.30 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.40 (up from ৳0.30 in 3Q 2021). Revenue: ৳38.0m (down 3.6% from 3Q 2021). Net income: ৳961.0k (up 34% from 3Q 2021). Profit margin: 2.5% (up from 1.8% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Dec 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: ৳5.42 loss per share (down from ৳1.52 profit in FY 2020). Revenue: ৳99.0m (down 65% from FY 2020). Net loss: ৳13.0m (down 458% from profit in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jun 27Full year 2020 earnings released: EPS ৳1.52 (vs ৳1.40 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ৳285.3m (down 11% from FY 2019). Net income: ৳3.64m (up 8.0% from FY 2019). Profit margin: 1.3% (up from 1.0% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Jun 23Upcoming dividend of ৳1.50 per shareEligible shareholders must have bought the stock before 29 June 2021. Payment date: 12 August 2021. Trailing yield: 0.4%. Lower than top quartile of Bangladeshi dividend payers (2.8%). Lower than average of industry peers (1.5%).
Is New 90 Day High Low • Feb 04New 90-day low: ৳417The company is down 9.0% from its price of ৳459 on 05 November 2020. The Bangladeshi market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.
Is New 90 Day High Low • Jan 20New 90-day low: ৳430The company is down 9.0% from its price of ৳474 on 22 October 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: ৳441The company is down 1.0% from its price of ৳446 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.
